methods have been used for determining the administered activity, varied from fixed doses to adjusted calculations based on gland size, iodine uptake and turnover (7) . The dose calculation method aims to optimize the therapeutic results through administration of radioactive iodine in proportional to the size of the gland, increasing the probability of cure and providing the lowest possible radiation dose to the rest of the body (8) . There is little evidence that using a calculated dose has any advantage over a fixed-dose regimen in preventing hypothyroidism or improvement in cure rate (9) , but it increases significantly the cost of the therapy owing to increase the procedure complexity (10) .
Taking in mind that the radioactive iodine therapy is relatively inexpensive, thus the increase in its cost to determine the administered activity must be clearly justified (10) .
There are some predictive factors associated with RAI-131 success rate. Previous works have shown lower treatment success rates in young male patients, more severe cases of hyperthyroidism (11) (12) , larger goiters (12) (13) and in cases with low or high pretreatment thyroid uptake (12) (14) . The influence of pretreatment with anti-thyroid drugs on the efficacy of radioiodine therapy is controversial. Some authors believe that the thyrostatic drugs methimazole (MMI) and propylthiouracil (PTU) have a radioresistance effect and can lead to half-life reduction and accelerate turnover (15) (16) (17) , but others have shown an effect confined to PTU only (18) .
Patients and Methods:
We retrospectively evaluated 321 hyperthyroid patients due to GD referred to the nuclear medicine unit, Kasr Al ainy hospital (NEMROK), Cairo University, during the period of January 2000 till January 2010 for RAI-131 therapy as first or as a second treatment modality (following medical or surgical treatment). Our 4 4 institutional medical ethics committee approved the protocol. The diagnosis of GD was primarily based on clinical (hyperthyroid manifestations and diffusely enlarged thyroid gland) and laboratory data, including high serum free T4 level (FT4; reference Values, RV = 0.9 -1.8 ng/dL) and low serum thyrotropin levels (TSH; RV = 0.41-4.5 µ IU/mL).
The patients who had thyrotoxicosis due to toxic multi-nodular goiter (Plummer disease), toxic autonomous adenoma, GD associated with (cold) nodule by (scan) or palpation respectively and patients who not completed the follow up were excluded from the study.
Data were retrieved from the thyroid clinic database include: age at diagnosis, gender, symptoms, dose and duration of anti-thyroid drugs , previous surgical treatment, clinical data for the presence of palpable nodules & other neck swellings and the presence or absence of eye signs, TSH level and thyroid scan using Tc-99m pertechnetate that was done 20 min after intravenous injection of 5 mCi of the tracer to evaluate the associated nonfunctioning (cold) nodule and quantitation of thyroid uptake using the methodology previously described by Maisey et al (19) and simplified for routine use. The reference values for Tc-99m pertechnetate uptake range from 0.3 to 4 % (20) . Gland size were determined by combining clinical examination (palpation) and thyroid scan and was divided in to either normal size (impalpable), mild (palpably enlarged but not visible) and moderate or markedly enlargement (palpable and visible goiter). In view of our socioeconomical circumstances; the simple fixed dose protocol has considerable cost saving advantages, we have adopted this protocol for the treatment of GD in our institution. The patients were divided according to the given RAI-131 dose in to 2 groups: Group 1: received 8 mCi (155 patients) (48.3%) and Group 2: received 12 mCi (166 patients) (51.7%), they are the commonly preferred doses in the treatment of GD in our institute.
Anti-thyroid drugs, if given before therapy, were withdrawn a week before therapy and for a minimum of 1 week after to avoid any drug influence on the therapeutic effectiveness. Iodine-containing medications were also discontinued several weeks before therapy; in addition, the patients were started on a low-iodine diet for 10 days before therapy, fasted before and for 2 hours after the administration of the dose to achieve higher absorption. Patients were advised to avoid physical contact and transfer of secretions to others for several days after treatment. Regular clinical and laboratory follow up to evaluate therapeutic efficacy was done and the patients were classified according to the outcome in to: Euthyroidism: Absence of signs or symptoms of hyperthyroidism or hypothyroidism with normal serum TSH value without levothyroxin therapy. Resistant to therapy: persistence of thyrotoxic manifestation and suppressed TSH value or by requirement of repeat administration of RAI-131 therapy within 6 months of the therapy and Hypothyroidism: presence of symptoms or signs of hypothyroidism together with elevated TSH value on two occasions four weeks apart, that require permanent treatment with levothyroxine. RAI-131 treatment was considered to be successful if the patient was either euthyroid or hypothyroid.
Statistical methods: Data was analyzed using IBM SPSS advanced statistics version 20 (SPSS Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation or median and range as appropriate. Qualitative data were expressed as frequency and percentage. Chi-square test (Fisher's exact test) was used to examine the relation between 6 qualitative variables. For quantitative data, comparison between two groups was done using Mann-Whitney test (non-parametric t-test). The receiver operator characteristic (ROC) curve was used to identify the best threshold for thyroid uptake to discriminate success and failure of RAI-131 therapy. Multivariate analysis was done using forward stepwise logistic regression method for the significant factors affecting response on univariate analysis. Odds ratio (OR) with 95% confidence interval (CI) were used for risk estimation. P-value < 0.05 was considered significant.
Results:. Baseline, pre-therapy clinical characteristics and commonly presenting symptoms for the patients are listed in Table 1 There was statistically significant difference in the incidence of early complications between the patients who received 8 mCi and the second group who received 12 mCi, in favor of the latter group (p = 0.024), whereas as there was no statistically significant difference between age, gender, presence of exopthaloms, size of thyroid gland and thyroid uptake and early complications either between the two groups as shown in the (25) demonstrated that methimazole pretreatment has no effect on the final treatment result, including the time required for cure or the 1-year success rate of RAI therapy.
Thientunyakit T et al. (26) showed that duration of anti-thyroid drug given prior to radioiodine therapy seemed not related to the treatment outcome. Moura-Neto also found that no statistically significant association between thyroid function outcome to a fixed, 15 mCi approach for treatment of Graves' hyperthyroidism and drug used (methi-mazole or propylthiouracil; maintenance or withdrawal of thionamides prior to therapy (27) . Our results were in agreement with the later ones, where we don't find statistical significant difference between pre-iodine medical treatment or its duration and the outcome to RAI-131 therapy.
Surgery is no longer recommended as first-line therapy for GD and use in selective cases where RAI is not preferred and ATDs fail to control the disease(3). Lal et al.
concluded that total thyroidectomy (TT) is much better than Subtotal thyroidectomy (STT) (28) . In the present study, STT was performed in only 49 patients (15.3%) with recurrent of disease in all of them at a median period of 66 months, confirming the literature data of using it as an alternative option in selected patients.
The size of thyroid gland is an important factor influencing the outcome of therapy; In our study, mildly enlarged glands had more controlled rate than moderate or markedly enlarged thyroid gland with higher incidence of hypothyroidism ( P = 0.042). This result is in agreement with the other multiple studies which have demonstrated that patients with larger-volume thyroid glands to fail to respond to a single dose of radioiodine (23-
27-29-30-31-32).
The impact of thyroid uptake on the RAI outcome has been investigated using either 131I or Tc99m pertechnetate. Alexander et al (12) found that patients who have higher 24-hour thyroid RAI uptake values were at higher risk than others for treatment failure. approach for treatment of GD and Tc-99m sodium pertechnetate thyroid uptake prior to therapy (27) . Tc-99 m pertechnetate uptake is routinely used in our department as a surrogate measure of thyroid uptake because it has been proved to possess a good correlation with iodide 125 uptake (34) . Moreover, it is much less expensive, reliable and convenient method allows uptake within 20 minutes after intravenous injection of the radionuclide and the therapeutic dose of RAI can be administered immediately after. We found that Tc-99m pertechnetate thyroid uptake more than 20.9% was among the poor prognostic factors for the response, thus higher dose is recommended.
The different RAI doses have different impact on the thyroid gland function, less than half of the patients (49%) in group 1 who received low dose of RAI achieved cure. On the other hand 69.4 % from the second group, who received higher dose of RAI, had achieved cure. This means that higher dose of RAI increase response rate by ~ 20.4 %.
Franklyn et al. (35) and Sankar et al.(36) studied the therapeutic outcome of low fixed dose of RAI, the former concluded that persistent hyperthyroidism after 6 months was present in 55.9% of the patients using small fixed dose of 5 mCi of RAI and the latter recommended increase dose of RAI to achieve response. This agree with Nordyke and Gilbert (29) who analyzed a series of 605 patients treated with RAI to find out the optimal dose to achieve cure and they concluded that cure was directly related to the dose of RAI administered and the optimal dose for curing hyperthyroidism is approximated by starting with 10 mCi and increasing it for unusually large glands or for special patient circumstances.
In the present study, 88% of patients achieved cure after administration of second dose of RAI with no statistically significant difference was found between the success rate and the given dose, only few patients require 3 rd or 4 th doses. This is in concordant with concluded that RAI therapy for GD is associated with definite increased risk of GO in around 20% of patients (either developing new cases or worsening of preexisting one).
However In the present work there was worsening of exophtalmus in 9.6 % of the patients and three new cases were developed (1.3%) among the rest who did not have prior exopthalmos, they were among the 177 patients who developed permanent hypothyroidism.
Conclusion: Radioiodine is clearly successful in curing hyperthyroidism in GD patients by 100 % after 4 doses; therefore it should be used as a first standard line in treatment.
Treatment results using fixed RAI dose are comparable to those studies of patients treated with RAI using the prescribed absorbed dose method. The standard-dose prescription strategy is therefore an efficient, cost-effective and is also convenient to the patient. It may be possible to improve cure rates using a single fixed-dose regimen without increasing the dose in all patients. This might be achieved by the identification of subjects with poor prognostic factors who are unlikely to respond to standard doses and by administering larger doses only to these individuals. A higher fixed (12 mCi) is more effective than lower dose (8 mCi) for treatment of GD leading to better control of the disease following the first dose. Higher response rate are expected in patients who underwent previous surgery, on contrary patients with larger goiters and high thyroid uptake > 20.9% had 3.3 and 4 times less chance of remission. This different impact of different doses on the response rate is applied to the first dose, but not to the second dose where the response rate to the second dose is nearly similar in both low and high dose groups. 
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Conclusions: I-131 is very effective therapy for Graves` disease with cure rate 100% after 4 doses. Higher first dose activity is recommended in the presence of poor prognostic factors. Second dose is not necessary increased in the non responders.
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Introduction: Graves` disease (GD) is the most common cause of hyperthyroidism responsible for approximately 50-60% of the cases (1). The most common clinical presentations related to the cardiovascular system. Other disease manifestations include
Graves' ophthalmopathy and myxedema (2) . Diagnostic modalities include suppressed serum TSH and an elevated serum FT4, FT3 levels, thyroid scintigraphy either with Tc99m pertechnetate or radioactive iodine-131 (RAI-131) and ultrasonography (U.S) to detect the presence of an associated nodules (3). Three therapeutic modalities are commonly used today; anti-thyroid drugs (ATDs), RAI-131 and surgical treatment (3).
The aim of RAI -131 treatment is to cure the hyperthyroidism by rendering the patient either euthyroid or hypothyroid through destruction of the over-functioning thyroid tissues (4). The use of RAI-131 in treatment of GD is increasing, particularly as a first line treatment (5) as it is easy to administer, relatively inexpensive, reliable , safe and highly effective with a cure rate approaching 100% after one or more dose (6) . Different methods have been used for determining the administered activity, varied from fixed doses to adjusted calculations based on gland size, iodine uptake and turnover (7). The dose calculation method aims to optimize the therapeutic results through administration of radioactive iodine in proportional to the size of the gland, increasing the probability of cure and providing the lowest possible radiation dose to the rest of the body (8) . There is little evidence that using a calculated dose has any advantage over a fixed-dose regimen in preventing hypothyroidism or improvement in cure rate (9), but it increases significantly the cost of the therapy owing to increase the procedure complexity (10).
Taking in mind that the radioactive iodine therapy is relatively inexpensive, thus the increase in its cost to determine the administered activity must be clearly justified (10).
There are some predictive factors associated with RAI-131 success rate. Previous works have shown lower treatment success rates in young male patients, more severe cases of hyperthyroidism (11)(12) , larger goiters (12) (13) and in cases with low or high pretreatment thyroid uptake (12) (14) . The influence of pretreatment with anti-thyroid drugs on the efficacy of radioiodine therapy is controversial. Some authors believe that the thyrostatic drugs methimazole (MMI) and propylthiouracil (PTU) have a radioresistance effect and can lead to half-life reduction and accelerate turnover (15) (16) (17) (51.7%), they are the commonly preferred doses in the treatment of GD in our institute.
Anti-thyroid drugs, if given before therapy, were withdrawn a week before therapy and for a minimum of 1 week after to avoid any drug influence on the therapeutic effectiveness. Iodine-containing medications were also discontinued several weeks before therapy; in addition, the patients were started on a low-iodine diet for 10 days before therapy, fasted before and for 2 hours after the administration of the dose to achieve using Mann-Whitney test (non-parametric t-test). The receiver operator characteristic (ROC) curve was used to identify the best threshold for thyroid uptake to discriminate success and failure of RAI-131 therapy. Multivariate analysis was done using forward stepwise logistic regression method for the significant factors affecting response on univariate analysis. Odds ratio (OR) with 95% confidence interval (CI) were used for risk estimation. P-value < 0.05 was considered significant.
Results:. Baseline, pre-therapy clinical characteristics and commonly presenting symptoms for the patients are listed in Table 1 Six of the 8 patients developed transient hypothyroidism after 1 st dose, while the remaining 2 patients developed it after 2 nd dose. Also neck pain developed in 2 patients.
There was statistically significant difference in the incidence of early complications between the patients who received 8 mCi and the second group who received 12 mCi, in favor of the latter group (p = 0.024), whereas as there was no statistically significant difference between age, gender, presence of exopthaloms, size of thyroid gland and thyroid uptake and early complications either between the two groups as shown in the table (3) or in each group separately (not included).
Exopthalmos was increased in 9 patients (9.6%) after RAI-131 therapy and remained stationary in rest. Three new cases (1.3%) developed exophthalmos from the remaining 7 227 patients and they were among the 170 patients who had permanent hypothyroidism (1.7%). No relation was found between the presence of exopthalmos and development of early complications as shown in tables 3.
The success rate to the first given dose was 59.8% with development of euthyroidism in 56 patients (17.4%) and hypothyroidism in 136 patients (42.4%). There was statistically significant difference in the successes rate between the patients who received 8 mCi (49%) and 12 mCi (69.9%) P <0.001. Of the 76 patients in whom therapy was successful in group1, 25 (16.1%) developed euthyroidism and 51(32.9 %) developed hypothyroidism and at a median period of 6 months (range: 3 -18 months) and among the 116 responding patients in the second group, euthyroidism was achieved in 37 patients (22.3%) and hypothyroidism in 79 patients (47.6%) with a median cure time 4 months (range: 2 -18 months).
There was no statistically significant association between age, presence of ophthalmopathy and previous medical treatment & its duration and outcome, whereas there was statistically significant difference regarding gender, size of thyroid gland, Tc99m pertechnetate thyroid uptake and previous surgical treatment as demonstrated in table 4. We did not find any relationship between the previous use of methimazole & its duration and the outcome of patients either in the whole study population or G1 and G2 separately (tables 4 and 5 A&B).
Thyroid uptake was analyzed using ROC curve to discriminate the group of patients who achieved success with treatment from the group that remained hyperthyroid and we found a thyroid uptake threshold of 20.9 % with a sensitivity of 76.1 % and specificity of 65.4 8 % for treatment success (Fig. 1 (25) demonstrated that methimazole pretreatment has no effect on the final treatment result, including the time required for cure or the 1-year success rate of RAI therapy.
The size of thyroid gland is an important factor influencing the outcome of therapy; In our study, mildly enlarged glands had more controlled rate than moderate or markedly enlarged thyroid gland with higher incidence of hypothyroidism ( P = 0.042). This result is in agreement with the other multiple studies which have demonstrated that patients with larger-volume thyroid glands to fail to respond to a single dose of radioiodine (23-27-29-30-31-32) .
Treatment results using fixed RAI dose are comparable to those studies of patients treated with RAI using the prescribed absorbed dose method. The standard-dose prescription strategy is therefore an efficient, cost-effective and is also convenient to the patient. It may be possible to improve cure rates using a single fixed-dose regimen without increasing the dose in all patients. This might be achieved by the identification of subjects with poor prognostic factors who are unlikely to respond to standard doses and by administering larger doses only to these individuals. A higher fixed (12 mCi) is more effective than lower dose (8 mCi) for treatment of GD leading to better control of the disease following the first dose. Higher response rate are expected in patients who underwent previous surgery, on contrary patients with larger goiters and high thyroid uptake > 20.9% had 3.3 and 4 times less chance of remission. This different impact of different doses on the response rate is applied to the first dose, but not to the second dose where the response rate to the second dose is nearly similar in both low and high dose groups.
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